HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

People who use popular diabetes drugs called GLP-1 receptor agonists may be at  increased risk for a serious eye disease, a ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

GLP-1 receptor agonists may aid smoking cessation by curbing cravings and mitigating weight gain, which often are impediments ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

The Obesity Society, along with several other organizations, jointly released a clinical advisory on nutritional priorities ...